TransMedics Group (HAM:8T8) Beneish M-Score: -1.32 (As of Jun. 29, 2026)


HAM:8T8 TransMedics Group Inc HAM:8T8
69 GF Score
Price €60.02
GF Value €162.08
! 9 Warning Signs
View Full Analysis

What is TransMedics Group Beneish M-Score?

TransMedics Group HAM:8T8 -9.99% 69 Beneish M-Score is -1.32 as of Jun. 29, 2026. GuruFocus rates HAM:8T8 with a GF Score™ of 69/100 and a GF Value™ of €162.08. The stock has 9 warning signs investors should review. Among 765 Medical Devices & Instruments companies, TransMedics Group ranks worse than 88.76% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.32 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for TransMedics Group's Beneish M-Score or its related term are showing as below:

HAM:8T8' s Beneish M-Score Range Over the Past 10 Years
Min: -3.16   Med: -2   Max: 4.73
Current: -1.32

During the past 10 years, the highest Beneish M-Score of TransMedics Group was 4.73. The lowest was -3.16. And the median was -2.00.


TransMedics Group Beneish M-Score Historical Data

* Premium members only.

The historical data trend for TransMedics Group's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransMedics Group Beneish M-Score Chart

TransMedics Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.16 -0.01 2.81 -2.05 -0.82

TransMedics Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.94 -2.48 -2.98 -0.82 -1.32

HAM:8T8 vs AXGN, BFLY, ESTA: Beneish M-Score Comparison

For the Medical Devices subindustry, TransMedics Group's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TransMedics Group Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where TransMedics Group's Beneish M-Score falls into.


HAM:8T8
69GF Score
TransMedics Group Inc HAM:8T8
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransMedics Group Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of TransMedics Group for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4951+0.528 * 1.0067+0.404 * 4.6566+0.892 * 1.2066+0.115 * 1.4328
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8712+4.679 * -0.044108-0.327 * 0.9573
=-1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €78.5 Mil.
Revenue was 150.452 + 137.292 + 122.537 + 136.44 = €546.7 Mil.
Gross Profit was 87.504 + 79.776 + 72.058 + 83.743 = €323.1 Mil.
Total Current Assets was €535.7 Mil.
Total Assets was €1,241.1 Mil.
Property, Plant and Equipment(Net PPE) was €606.3 Mil.
Depreciation, Depletion and Amortization(DDA) was €28.3 Mil.
Selling, General, & Admin. Expense(SGA) was €170.6 Mil.
Total Current Liabilities was €79.5 Mil.
Long-Term Debt & Capital Lease Obligation was €730.8 Mil.
Net Income was 6.327 + 89.997 + 20.72 + 30.264 = €147.3 Mil.
Non Operating Income was 2.04 + 10.01 + 0.085 + 0.52 = €12.7 Mil.
Cash Flow from Operations was 21.221 + 29.474 + 59.276 + 79.425 = €189.4 Mil.
Total Receivables was €131.4 Mil.
Revenue was 132.772 + 116.151 + 97.994 + 106.189 = €453.1 Mil.
Gross Profit was 81.611 + 68.772 + 54.821 + 64.343 = €269.5 Mil.
Total Current Assets was €468.0 Mil.
Total Assets was €774.7 Mil.
Property, Plant and Equipment(Net PPE) was €293.5 Mil.
Depreciation, Depletion and Amortization(DDA) was €20.0 Mil.
Selling, General, & Admin. Expense(SGA) was €162.3 Mil.
Total Current Liabilities was €51.4 Mil.
Long-Term Debt & Capital Lease Obligation was €476.9 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(78.479 / 546.721) / (131.374 / 453.106)
=0.143545 / 0.289941
=0.4951

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(269.547 / 453.106) / (323.081 / 546.721)
=0.594887 / 0.590943
=1.0067

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (535.677 + 606.343) / 1241.119) / (1 - (467.974 + 293.457) / 774.715)
=0.079846 / 0.017147
=4.6566

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=546.721 / 453.106
=1.2066

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(20.037 / (20.037 + 293.457)) / (28.311 / (28.311 + 606.343))
=0.063915 / 0.044609
=1.4328

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(170.597 / 546.721) / (162.28 / 453.106)
=0.312037 / 0.35815
=0.8712

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((730.845 + 79.511) / 1241.119) / ((476.948 + 51.433) / 774.715)
=0.652924 / 0.682033
=0.9573

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(147.308 - 12.655 - 189.396) / 1241.119
=-0.044108

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

TransMedics Group has a M-score of -1.40 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.32 mean?
TransMedics Group (HAM:8T8) has a Beneish M-Score of -1.32 as of Jun. 29, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on TransMedics Group and its competitors. According to the industry distribution chart, TransMedics Group ranks #679 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 88.8%.
Is TransMedics Group's Beneish M-Score too high?
TransMedics Group's current Beneish M-Score is -1.32. Based on the distribution chart, TransMedics Group ranks #679 out of 765 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TransMedics Group has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's Beneish M-Score compare to AXGN and BFLY?
According to the Medical Devices & Instruments industry distribution chart, TransMedics Group ranks #679 out of 765 companies for Beneish M-Score. This places TransMedics Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on TransMedics Group and its competitors. TransMedics Group's current Beneish M-Score is -1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
TransMedics Group (HAM:8T8) has a current Beneish M-Score of -1.32. The stock's GF Value™ is €162.08, compared to a current price of €60.02 — trading 63% below its estimated fair value. The current Beneish M-Score is -1.32. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For TransMedics Group (HAM:8T8), the current Beneish M-Score is -1.32 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TransMedics Group (HAM:8T8) Overvalued in 2026?

Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued. The current stock price of €60.02 is trading 63% below its estimated GF Value™ of €162.08.

Key valuation signals for HAM:8T8:

  • Beneish M-Score: -1.32
  • GF Value™: €162.08 vs. price of €60.02 (63% below fair value)
  • GF Score™: 69/100 with 9 warning signs

No single metric tells the full story. See the HAM:8T8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TransMedics Group Business Description

Address 200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score

Get the complete analysis for HAM:8T8

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.02
Price
€162.08
GF Value